AR012448A1 - Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada - Google Patents

Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada

Info

Publication number
AR012448A1
AR012448A1 ARP980101756A ARP980101756A AR012448A1 AR 012448 A1 AR012448 A1 AR 012448A1 AR P980101756 A ARP980101756 A AR P980101756A AR P980101756 A ARP980101756 A AR P980101756A AR 012448 A1 AR012448 A1 AR 012448A1
Authority
AR
Argentina
Prior art keywords
substance
mixture
polymer
active
microcapsules
Prior art date
Application number
ARP980101756A
Other languages
English (en)
Original Assignee
Ipsen Pharma Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233477&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR012448(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9704837A external-priority patent/FR2762318B1/fr
Priority claimed from FR9803666A external-priority patent/FR2776516B1/fr
Application filed by Ipsen Pharma Biotech filed Critical Ipsen Pharma Biotech
Publication of AR012448A1 publication Critical patent/AR012448A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a composiciones en forma de micro-cápsulas o implantes, que comprende un excipiente polimérico o copolimérico, bio-degradable, o una mezcla de dichos excipientes, con una viscosidad inherente de entre 0,5 dl/g y 1,6 dg/l en CHCl3, y una sustancia activa o una mezcla desustancias activas, siendo posible que dichas microcápsulas o implantes liberen la sustancia activa, o mezcla de sustancias activas, a lo largo de unprolongado período, de hasta tres meses o más. Dichas composiciones también pueden contener un principio activo de elevada área superficial específica.
ARP980101756A 1997-04-18 1998-04-16 Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada AR012448A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9704837A FR2762318B1 (fr) 1997-04-18 1997-04-18 Compositions presentant une liberation prolongee et leur procede de preparation
FR9803666A FR2776516B1 (fr) 1998-03-25 1998-03-25 Compositions presentant une liberation prolongee et leur procede de preparation

Publications (1)

Publication Number Publication Date
AR012448A1 true AR012448A1 (es) 2000-10-18

Family

ID=26233477

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980101756A AR012448A1 (es) 1997-04-18 1998-04-16 Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
ARP070102999A AR061828A2 (es) 1997-04-18 2007-07-05 Procedimiento para la preparacion de una sustancia soluble en agua de elevada area superficial especifica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070102999A AR061828A2 (es) 1997-04-18 2007-07-05 Procedimiento para la preparacion de una sustancia soluble en agua de elevada area superficial especifica

Country Status (23)

Country Link
US (2) US6217893B1 (es)
EP (1) EP0980240B1 (es)
JP (1) JP4557312B2 (es)
CN (2) CN1144584C (es)
AR (2) AR012448A1 (es)
AT (1) ATE389388T1 (es)
AU (1) AU741964B2 (es)
BR (1) BR9808933A (es)
CA (1) CA2286575C (es)
CZ (1) CZ297078B6 (es)
DE (1) DE69839264T2 (es)
DK (1) DK0980240T3 (es)
ES (1) ES2303353T3 (es)
HK (1) HK1027983A1 (es)
HU (1) HUP0004297A2 (es)
IL (1) IL132217A (es)
MY (1) MY118835A (es)
NO (2) NO327999B1 (es)
PL (1) PL196771B1 (es)
PT (1) PT980240E (es)
RU (1) RU2198678C2 (es)
TW (1) TW577759B (es)
WO (1) WO1998047489A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6303138B1 (en) * 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
CA2405563A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP2004528089A (ja) * 2001-04-17 2004-09-16 ユニバーシティ・オブ・シェフィールド メラニン細胞刺激ホルモン（ｍｓｈ）を含む生体適合材料および形成方法
EP1401477A4 (en) * 2001-05-25 2005-02-02 Human Genome Sciences CHIMIOKINE BETA-1 HYBRID PROTEINS
EP1408876A4 (en) 2001-06-22 2004-09-22 Durect Corp ZERO ORDER COAXIAL IMPLANTS WITH EXTENDED RELEASE
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
MXPA05002991A (es) * 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en) * 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
DE04758472T1 (de) * 2003-03-26 2005-06-23 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung eines pharmazeutischen wirkstoffs mit hochspezifischer oberfläche
US20070027073A1 (en) * 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
BRPI0409032A (pt) 2003-04-10 2006-05-02 Pr Pharmaceuticals método para a produção de micropartìculas à base de emulsão
EP1620060B1 (en) * 2003-04-29 2010-03-24 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US8871269B2 (en) * 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
BRPI0412211A (pt) * 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
US8846874B2 (en) * 2003-11-13 2014-09-30 Hanmi Science Co., Ltd IgG Fc fragment for a drug carrier and method for the preparation thereof
WO2005067889A1 (en) * 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
EP1734971B8 (en) 2004-04-15 2012-02-29 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7919577B2 (en) 2004-10-27 2011-04-05 Colorado Seminary Adrenocorticotropic hormone analogs and related methods
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1853227B1 (en) * 2005-03-02 2009-08-05 The Secretary of State for Defence Pharmaceutical composition
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
AR058591A1 (es) * 2005-12-22 2008-02-13 Novartis Ag Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido
KR101728868B1 (ko) * 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
ES2398126T3 (es) 2006-08-09 2013-03-13 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
US20080233199A1 (en) * 2007-03-22 2008-09-25 Alkermes, Inc. Coacervation Process
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
CA2688478C (en) * 2007-06-06 2015-10-27 Debio Recherche Pharmaceutique S.A. Slow release pharmaceutical composition made of microparticles
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
KR101921800B1 (ko) * 2008-01-30 2018-11-23 노파르티스 아게 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
MX352189B (es) * 2008-09-04 2017-11-10 Amylin Pharmaceuticals Llc Formulaciones de liberación sostenida usando portadores no acuosos.
NZ747990A (en) 2009-09-28 2020-06-26 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA2784394C (en) * 2010-01-04 2016-12-13 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
IT1402654B1 (it) * 2010-09-20 2013-09-13 Cid S R L Composizione per il rilascio di principi attivi da dispositivi di impianto
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103163258B (zh) * 2011-12-09 2015-09-23 山东绿叶制药有限公司 一种测定痕量曲普瑞林的方法
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CN104394980B (zh) * 2012-03-08 2018-10-09 康斯乔最高科学研究公司 具有光致变色性质的涂层、产生所述涂层的方法及其适用于光学制品和光滑表面的用途
BR112014026957A8 (pt) 2012-05-03 2018-01-16 Janssen R&D Ireland micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
RU2506269C1 (ru) * 2012-08-03 2014-02-10 Татьяна Георгиевна Емельянова Фармацевтическая композиция, содержащая физиологически активные гептапептиды, обладающие противосудорожным, анксиолитическим, центральным противовоспалительным и анальгетическим, а также антиалкогольным действием
WO2014169816A1 (zh) * 2013-04-18 2014-10-23 山东绿叶制药有限公司 戈舍瑞林缓释微球药物组合物
CN103230624A (zh) * 2013-05-02 2013-08-07 复旦大学附属上海市第五人民医院 一种用于微创埋线治疗的植入材料
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
NZ738102A (en) 2015-06-03 2024-02-23 Intarcia Therapeutics Inc Implant placement and removal systems
CN107690333B (zh) * 2015-06-10 2021-12-17 赢创运营有限公司 制备包含人凝血因子蛋白和乳酸聚合物的粉末的方法
CN107224571A (zh) * 2016-03-23 2017-10-03 张巍 一种具有坐骨神经保护功能的plga复合微球
ITUA20162094A1 (it) 2016-03-29 2017-09-29 Cid S P A Perfezionamenti negli stent per il rilascio di principi attivi
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
TWI814219B (zh) 2016-05-16 2023-09-01 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN107375910B (zh) * 2017-07-12 2020-03-24 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 PTHrP在制备治疗男性性腺功能低下综合征中的应用
CN110547969A (zh) * 2019-09-03 2019-12-10 杭州诺泰澳赛诺医药技术开发有限公司 一种高比表面积纳米级缓释微粉的生产工艺及设备
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
CN112156170B (zh) * 2020-11-03 2022-10-21 北京康欣东弘医药科技有限公司 可供皮下注射的曲普瑞林缓释微球及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
CN100391445C (zh) * 1996-01-24 2008-06-04 美国政府陆军部 新型的“非突发的”持续释放聚(丙交酯/乙交酯)的微球
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5021554A (en) 1989-02-24 1991-06-04 Eli Lilly And Company Process for protein particle size reduction using a fluid-energy mill
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
GB2246514B (en) * 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
FR2693905B1 (fr) 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
ATE236655T1 (de) * 1993-01-06 2003-04-15 Kinerton Ltd Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6136346A (en) * 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
DE69614685T2 (de) * 1995-06-07 2002-06-27 Alkermes Inc Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada

Also Published As

Publication number Publication date
CN1256628A (zh) 2000-06-14
US6475507B1 (en) 2002-11-05
IL132217A0 (en) 2001-03-19
NO995063L (no) 1999-11-15
JP4557312B2 (ja) 2010-10-06
PL196771B1 (pl) 2008-01-31
AU741964B2 (en) 2001-12-13
ES2303353T3 (es) 2008-08-01
ATE389388T1 (de) 2008-04-15
HUP0004297A2 (hu) 2001-08-28
CA2286575A1 (fr) 1998-10-29
NO327999B1 (no) 2009-11-09
CN1313082C (zh) 2007-05-02
AU7436398A (en) 1998-11-13
CA2286575C (fr) 2012-06-05
US6217893B1 (en) 2001-04-17
AR061828A2 (es) 2008-09-24
MY118835A (en) 2005-01-31
PL336296A1 (en) 2000-06-19
TW577759B (en) 2004-03-01
DE69839264T2 (de) 2009-05-14
IL132217A (en) 2004-08-31
CZ297078B6 (cs) 2006-09-13
CZ362699A3 (cs) 2000-04-12
CN1494900A (zh) 2004-05-12
RU2198678C2 (ru) 2003-02-20
HK1027983A1 (en) 2001-02-02
EP0980240A1 (fr) 2000-02-23
NO20080803L (no) 1999-11-15
EP0980240B1 (fr) 2008-03-19
JP2002500631A (ja) 2002-01-08
WO1998047489A1 (fr) 1998-10-29
DE69839264D1 (de) 2008-04-30
DK0980240T3 (da) 2008-07-28
BR9808933A (pt) 2000-08-01
NO995063D0 (no) 1999-10-15
PT980240E (pt) 2008-06-06
CN1144584C (zh) 2004-04-07

Similar Documents

Publication Publication Date Title
AR012448A1 (es) Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
IL142470A0 (en) Controlled release liquid delivery compositions with low initial drug burst
ME00867B (me) Tečne polimerne smeše za kontrolisano oslobađanje bioaktivnih supstanci
WO2001015734A3 (en) High viscosity liquid controlled delivery system and medical or surgical device
DE60017956D1 (de) Biodegradierbare polymerzusammensetzung
CA2430481A1 (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
DE69721481D1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
DK0643963T3 (da) Biologisk nedbrydelig indretning til indgivelse af virksomme stoffer
AR008060A1 (es) Una formulacion no acuosa de peptidos y un metodo para prepararla
WO2001091725A3 (en) Biologically useful polyphosphates
DE69121675D1 (de) Mikrosphäre enthaltende pharmazeutische Zusammensetzung mit kontrollierter Freigabe und Verfahren zur Herstellung
WO2004052336A3 (en) High viscosity liquid controlled delivery system and medical or surgical device
BRPI0012588B8 (pt) copolímero em bloco, composição para suprimento de agente bioativo, e, formulação de medicamento para implantação subcutânea ou injeção intravenosa.
CA2315115A1 (en) Compositions of microspheres for wound healing
EP0359402A3 (en) Long lasting contraceptive suppository composition and methods of use
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
CA2385890A1 (en) Controlled release compositions comprising nimesulide
BR9814756A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, uso de um grande número de pequenas esferas que contêm uma matriz polimérica composta de um polietileno glicol ou de uma mistura de polietileno glicóis
DE69901487D1 (de) Eine didemnin verbindung enthaltende pharmazeutische formulierung
ES2127556T3 (es) Cuerpo de moldeo implantable para la administracion de sustancias activas a plantas.
CO5170438A1 (es) Proceso para la preparacion de un comprimido de betahistina de liberacion controlada por granulacion en estado fundido y comprimido de liberacion controlada de betahistina obtenido mediante dicho proceso
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PT920336E (pt) Pesticidas que compreendem alcaloides da benzofenantridina
AU2002353661A1 (en) Biodegradable polymeric material for biomedical applications

Legal Events

Date Code Title Description
FC Refusal